P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001)

Slični predmeti

• PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
  od: Anand Patel, i dr.
  Izdano: (2023-08-01)
• Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
  od: Yvyin Zhang, i dr.
  Izdano: (2023-01-01)
• The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report
  od: Yueru Ji, i dr.
  Izdano: (2024-07-01)
• Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML
  od: Taner TAN, i dr.
  Izdano: (2025-01-01)
• SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
  od: Puissant, Alexandre, i dr.
  Izdano: (2017)